News: Study results suggest that in people with #Type2Diabetes , sulfonylurea treatment after metformin monotherapy is not significantly associated with elevated CV risk or all-cause mortality Diabetes Care, a research journal of the ADA 🌟 Andy Collier John Petrie Fraser Gibb bit.ly/3L1kZza

News: Researchers find an increased risk for future #Type2Diabetes in pregnant women with impaired glucose tolerance below the threshold for gestational diabetes The Lancet Diabetes & Endocrinology bit.ly/3ZHAUI3

News: Researchers report improved glucose control in young children with #Type1Diabetes using the Tandem Control-IQ closed-loop system, with virtual training and initiation in most cases NEJM UVA Health Center for Diabetes Technology bit.ly/40MyMj7

News: Risk for fracture “marginally” but significantly increased in people with #Type2Diabetes , suggest study results published in PLOS Medicine Göteborgs universitet / University of Gothenburg bit.ly/3K9iziu

Better informed doctors make better decisions. Which is why we are launching Springer Medicine, a pan-European, English-language, medical education platform.

Read our thread to learn more. 1/10

News: Randomized trial extends beta-cell-preserving benefits of verapamil to children with new-onset #Type1Diabetes but role for intensive glycemic control is “laid to rest” Jaeb Center for Health Research JAMA bit.ly/40p34IB

News: People with #Type2Diabetes who initiate intermittently scanned (flash) continuous glucose monitoring are also more likely to receive treatment intensification, researchers report in Diabetes, Obesity and Metabolism Wiley Clinical Health Western University bit.ly/3ZwPjrh

#ATTD2023 news: A pragmatic health informatics system can help physicians prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, reported Janaka Karalliedde (Guy's and St Thomas') Advanced Technologies & Treatments for Diabetes #Type1Diabetes #Type2Diabetes bit.ly/3KY6Iox

#ATTD2023 news: Arriving at an initial specialist consultation with 14 days of isCGM data may help people with #Type2Diabetes maximize benefit from the appointment, even if they subsequently return to self-monitored blood glucose Akshay Jain MD, FRCPC, FACE Advanced Technologies & Treatments for Diabetes bit.ly/3J5Gyyt

#ATTD2023 news: Initiating intermittently scanned CGM leads to real-world improvements in HbA1c and diabetes distress in people with #Type1Diabetes psychosocial indications, Harshal Deshmukh MBBS MRCP MPH PhD CCT 🇮🇳🇬🇧
(@UniOfHull) and co-researchers report Advanced Technologies & Treatments for Diabetes bit.ly/3Z4V92Q

News: A study pinpoints hypertension as the strongest mortality predictor in younger people with #Type2Diabetes but CKD as the key factor in the oldest people Andrea Luk Hongjiang WU Aimin Yang Dr Ronald Ma Elaine Chow PLOS Medicine bit.ly/3SryQln

News in brief: The extension to the ALERTT1 trial shows sustained improvements in time in range 2 years after switching from flash/intermittently scanned to real-time CGM #Type1Diabetes The Lancet Diabetes & Endocrinology bit.ly/3lH3jzS

News: Overweight and #obesity is very common in Americans with #Type1Diabetes and lifestyle advice is often not given or followed, Michael Fang (Johns Hopkins Bloomberg School of Public Health) Liz Selvin Justin Echouffo Tcheugui & colleagues report in Annals of Int Med Johns Hopkins Epidemiology JHU Welch Center bit.ly/3XwN710

News: A meta-analysis of GLP-1RA trials suggests benefits for new-onset but not preexisting #HeartFailure in people with #Type2Diabetes Francisca Saraiva DAVIDE CARVALHO Faiez ZANNAD bit.ly/3RFMGAl

News: The DINAMO investigators report “clinically relevant” HbA1c improvements with empagliflozin, but not linagliptin, in young people with #Type2Diabetes The Lancet Diabetes & Endocrinology @TomDanne bit.ly/3HoVnKE

News: A single autoantibody screen at age 10 years is sufficient to gauge #Type1Diabetes risk through age 18 in adolescents with high familial risk The Lancet Child & Adolescent Health mohamed.ghalwash bit.ly/3wv6PPO

News: Healthy lifestyle habits reduce the risk for microvascular complications of #Type2Diabetes in real-world data from UK Biobank. Published in PLOS Medicine with Perspective from Dr Yogini Chudasama Prof Kamlesh Khunti bit.ly/3GMfF0j

News: A fibre-enriched nutritional supplement improves quality of life in people with #Type2Diabetes and may improve glycaemic control, shows a randomised trial from Christopher Damman Chris Damman MD MA 🍓 (@UW) and co-researchers Wiley Clinical Health #Microbiome bit.ly/3wqpbSd

News: Analysis of Look AHEAD data shows that controlling blood glucose may minimise progression of #frailty in people with #Type2Diabetes Stephen Kritchevsky Diabetes Care, a research journal of the ADA 🌟 bit.ly/3W9kV3F

News: The EXPECT trial findings demonstrate noninferiority of insulin degludec to detemir in pregnant women with #Type1Diabetes Fidelma dunne Rosa Corcoy 😷 #YoTambienMeVacuno The Lancet Diabetes & Endocrinology bit.ly/3GTmJJQ